Table 4 Patient characteristics in the prevention group
Characteristics | Experimental group | Control group | p value |
|---|---|---|---|
n (%) | n (%) | ||
Age | p = 0.368 | ||
≥ 65 years | 16(47.1) | 10(35.7) | |
< 65 years | 18(52.9) | 18(64.3) | |
Gender | p = 0.368 | ||
Male | 16(47.1) | 10(35.7) | |
Female | 18(52.9) | 18(64.3) | |
Tumour site | p = 0.311 | ||
Head and neck | 0(0) | 1(3.6) | |
Chest | 15(44.1) | 17(60.7) | |
Abdomen | 18(52.9) | 9(32.1) | |
Other | 1(2.9) | 1(3.6) | |
PS | p = 0.990 | ||
0 | 4(11.8) | 3(10.7) | |
1 | 7(20.6) | 6(21.4) | |
2 | 23(67.6) | 19(67.9) | |
Chemotherapeutic drugs | p = 0.857 | ||
Platinum ± 5-FU | 15(44.1) | 16(57.1) | |
Paclitaxel | 10(29.4) | 7(25) | |
EN Huan | 1(2.9) | 1(3.6) | |
Target | 6(17.6) | 3(10.7) | |
Other | 2(5.9) | 1(3.6) | |